25th Anniversary Of Anti-AIDS Drugs
Elsevier journal Antiviral Research publishes milestone Special Issue
Amsterdam, March 3, 2010 – Elsevier, the world-leading publisher of scientific, technical and medical information products and services, released a special issue of the journal Antiviral Research, marking the 25th anniversary of antiretroviral drug development. The guest editors, José Esté from Hospital Germans Trias i Pujol, Barcelona, Spain and Tomas Cihlar, from Gilead sciences Inc., CA, USA were able to attract the key players in the field who all contributed a variety of review articles to this special issue, thereby creating a must-read for anybody interested in AIDS treatment.
In his review article, introducing this special issue of Antiviral Research, Samuel Broder from the Celera Corporation in Alameda, CA, USA, describes how in the last 25 years, HIV-1 has gone from being an ‘inherently untreatable’ infectious agent to one eminently susceptible to a range of approved therapies. In the late 1980s his group, then at the National Cancer Institute, played a key role in the discovery and development of the first generation of antiretroviral agents.
Physicians now have approximately 30 antiretroviral products, formulated either alone or in combination, to treat patients with human immunodeficiency virus (HIV-1), the pathogenic retrovirus which causes the acquired immunodeficiency syndrome (AIDS) and related conditions. Most are oral medicines, administered on convenient schedules. Several have been specially formulated as fixed-dose, generic-drug combinations for even greater utility in resource-poor nations.
In 2010 the journal Antiviral Research will celebrate its 30th anniversary by organizing an Antivirals Congress from 7-9 November 2010 in Amsterdam, the Netherlands (www.antivirals.elsevier.com). Floris de Hon, the Executive Publisher of the journal stated: “The guest editors and various authors of this milestone publication on anti-AIDS drugs will present at the Congress, which promises to serve as an interface between academics, those in research and development, regulatory and governmental agencies, charities, and health and industry professionals”.
# # #
Notes to Editors:
To receive a copy of Antiviral Research, Volume 85, Issue 1, January 2010; Special Issue – Twenty-five Years of Antiretroviral Drug Development: Progress and Prospects (Guest editors José Esté and Tomas Cihlar), please contact the Marketing Communication Manager of Antiviral Research at firstname.lastname@example.org.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
+44 1865 843 181